Newsletter Subject

Daily Headlines: Is PSA Testing Flawed, Or Is the Trial Design?

From

medpagetoday.com

Email Address

daily.headlines@broadcaster3.medpagetoday.com

Sent On

Wed, Sep 6, 2017 12:11 PM

Email Preheader Text

Daily Headlines September 6, 2017 Additional Resources Industry Resources [Official Site for HCPs Le

Daily Headlines September 6, 2017 [Is PSA Testing Flawed, Or Is the Trial Design?]( [PCSK9 Drugs Upgraded in Lipid Recs]( [Risk Factors for Rapid Glaucoma: Ophthalmology Times]( [iMedicalApps: App Tracks Vitamin D]( [The Perils of the Mid-Sized ED]( Additional Resources [Diagnosis and Treatment of Relapsed Myeloma]( [AML: Beware of Pre-leukemic Clones Surviving Chemotherapy]( [Support for Omitting ALND in Early Breast Cancer]( Industry Resources [Multiple Myeloma Potential Immuno-Oncology 2nd Line Treatment for Multiple Myeloma]( [CGRP Pathway and Migraine MDs, Watch a Video on Migraine and The Science Behind It]( [Official Site for HCPs Learn About Repatha® (evolocumab) by Visiting the Official Website]( Recent Headlines [Defining 'High Performance Care' Remains Elusive: HealthLeaders Media]( [Nurse Residencies in Post-Acute Care Hinge on Leadership]( [Shingles: A Link to Vasculitis?]( CME/CE [What Animals Yawn Contagiously? That's Improbable!]( [Does Biologic Risk Tolerance Vary?]( ADVERTISEMENT This Week's Survey [Time to Change Nutritional Guidelines?]( [Findings from a]([large study]( run counter to national dietary recommendations, suggesting that high-fat diets are beneficial and that fruits and veggies are best in moderation CME Spotlights [MDS and Acute Myeloid Leukemia (MDS and AML) @Point of Care]( [Source: @Point of Care]( [Skin Cancers @Point of Care]( [Source: @Point of Care]( [Outcomes in NSCLC: A Focus on Quality Improvement-Part1]( [Source: RMEI Medical Education]( [Treatment of a Relapsing High-Risk Multiple Myeloma Patient]( [Source: Projects In Knowledge, Inc.]( [Hematology CLL @POC]( [Source: @Point of Care]( [Multiple Myeloma (MM) @Point of Care|Grant|App]( [Source: @Point of Care]( [Treatment of Platinum-Resistant Recurrent Ovarian Epithelial Cancer]( [Source: Projects in Knowledge, Inc.]( [Treatment of Recurrent Cervical Squamous Cell Carcinoma]( [Source: Projects In Knowledge, Inc.]( [Role of Immunomodulatory Drug Therapy in a Patient with Refractory Multiple Myeloma]( [Source: Projects In Knowledge, Inc.]( [Newly Diagnosed Metastatic Prostate Cancer Patient]( [Source: Projects In Knowledge, Inc.]( [Relapsing-Remitting Multiple Sclerosis Patient Who Relapses on Current Treatment]( [Source: Projects In Knowledge, Inc.]( [A Multidisciplinary Approach to Management in Basal Cell Carcinoma]( [Source:Postgraduate Institute for Medicine and DKBMed]( [Basal Cell Carcinoma: A Comprehensive Team Approach to Management]( [Source:Postgraduate Institute for Medicine and DKBMed]( [Breast Cancer @POC]( [Source: @Point of Care]( [Evidence-Based Patient-Centered Management in NSCLC]( [Source: Postgraduate Institute for Medicine and DKBMed]( [Approaches to Managing the Complex Patient with NSCLC]( [Source: Postgraduate Institute for Medicine and DKBMed]( [Biosimilar vs. Generic... Are they the same? What do you say to your patient?]( [Source: France Foundation]( [Managing Treatment-Related Diarrhea in a Patient With MDS]( [In this case study, Donald P. Kotler, MD, examines the possible causes and solutions for lenalidomide-related diarrhea in a patient with MDS. Source:Clinical Care Options]( [Relapsing/Refractory Multiple Myeloma in a High Risk Patient]( [Source: Projects in Knowledge]( More of Today's Stories [AAP: Still a 'No' to FluMist for Upcoming Flu Season]( [How to Make the Most of Clinical Rotations]( [TNBC: Novel Targetable Pathways Under Active Investigation]( [A Call for Transparency in Healthcare Pricing]( [USPSTF: Do Vision Checks in Preschoolers]( [Pelzman's Picks: The True Value of Teamwork]( [New Tool Predicts OA Progress: Rheumatology Network]( [Pearls From: Steven Nissen, MD]( [NeuroBreak: Psychedelic 'Breakthrough' for PTSD; Opioid Gene Test Firm Falls Apart]( [Neurological Events Rare with Anti-PD-1 Therapy]( CME/CE [Biomarker Predicts CKD Progression in Kids]( CME/CE [MS Drug Works in Kids]( [Surgery and Legislation: All in a Day's Work for Greg Murphy, MD]( More news from MedPage Today® Meeting Coverage Can't get away? MedPage Today brings you extensive coverage of more than 80 meetings in a wide range of specialties. [EverydayHealth] © Copyright 2017 Everyday Health, Inc. All rights reserved. Use of this site constitutes acceptance of the MedPageToday.com [terms of use]( and [privacy policy.]( The material on this site is for informational purposes only, and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address:{EMAIL} [Manage my e-mail settings]( | [Unsubscribe from "Daily Headlines"](lst=Daily%20Headlines) Technical Questions: feedback@medpagetoday.com 345 Hudson Street 16th Floor New York, NY 10014

Marketing emails from medpagetoday.com

View More
Sent On

30/06/2024

Sent On

30/06/2024

Sent On

29/06/2024

Sent On

29/06/2024

Sent On

28/06/2024

Sent On

28/06/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.